Shopping Cart
- Remove All
- Your shopping cart is currently empty
BCAT-IN-1 is a potent, selective, and orally active inhibitor of BCATm, with a pIC50 of 7.3, exhibiting 100-fold greater selectivity for BCATm over BCATc (pIC50=5.4). BCAT-IN-1 is suitable for metabolic disease research [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $235 | 6-8 weeks | |
25 mg | $1,530 | 6-8 weeks | |
50 mg | $1,990 | 6-8 weeks | |
100 mg | $2,980 | 6-8 weeks |
Description | BCAT-IN-1 is a potent, selective, and orally active inhibitor of BCATm, with a pIC50 of 7.3, exhibiting 100-fold greater selectivity for BCATm over BCATc (pIC50=5.4). BCAT-IN-1 is suitable for metabolic disease research [1]. |
In vitro | BCAT-IN-1 (compound 8b) inhibits human BCATm with a pIC50 of 7.0 and mouse BCATm in a cellular assay with a pIC50 of 5.9 [1]. |
In vivo | BCAT-IN-1 (compound 8b), administered orally at doses ranging from 30 to 300 mg/kg, elevates c BCAA levels in an acute mouse model for an extended period [1]. At a lower dose of 5 mg/kg via oral route, BCAT-IN-1 demonstrates an oral bioavailability (F=28%) and a peak concentration (C max) of 1648 ng/mL in mice [1]. When given intravenously at 1 mg/kg, it shows a half-life (t 1/2 =9.2 hours) and a clearance rate (Cl=4.0 mL/min/kg) in mice [1]. |
Molecular Weight | 538.46 |
Formula | C25H24BrN5O2S |
Cas No. | 2581243-32-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.